This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
46


nanotimes


Companies Facts


coated condom. Starpharma terminates condom coating agreement with Reckitt Benckiser. The first of these is that, due to the failure to achieve satisfactory progress in relation to certain commer- cialisation milestones for the VivaGel®


the positive results of its first study of VivaGel® for -coated con-


dom, Starpharma’s Board has taken the decision to terminate the Licence granted to Reckitt Benckiser (RB; formerly SSL International plc) to commercialise the VivaGel®


-coated condom and all of RB’s rights


to the product, effective immediately. Starpharma is extremely disappointed to have to take this action but after full consideration of the situation, Directors and Management believe it to be the best course of action to ensure timely commercialisation and maxi- mise returns for the VivaGel®


-coated condom.


The second development is that Starpharma has executed a Licence Agreement with Ansell Limi- ted (ASX:ANN) giving Ansell marketing rights to the VivaGel®


-coated condom. The Agreement covers


marketing rights to the coated condom in countries which exclude Japan and a number of Asian markets.


Under the agreement Ansell will pay Starpharma royalties on sales of VivaGel®


-coated condoms and


will support registration and other commercialisation costs. Ansell is also responsible for manufacturing the VivaGel®


duct, which will include the VivaGel® with the respective Ansell brand.


-coated condom and marketing of the pro- brand together


Furthermore, Starpharma announced the commence- ment of its Phase 2 study of VivaGel®


for the preven-


tion of bacterial vaginosis (BV), following receipt of ethics approval. The prevention of BV is the second area of investigation of the VivaGel®


condition. In May 2011, Starpharma announced product for this


the treatment of BV, which showed that the product successfully treated patients suffering the illness, with very high levels of patient acceptability. Further dis- cussions with the US Food and Drug Administration (FDA) and other regulators on the development of VivaGel®


for the treatment of BV will occur over the


next few months, with Phase 3 studies for BV treat- ment expected to commence in late 2011 or early 2012. This new phase of the program will investigate the ability of VivaGel®


to prevent recurrence of BV,


which clinicians identify as a major unmet need. The trial will be conducted in women with a prior history of recurrent BV, and the product will be used every second day.


Starpharma released its annual report and financial results for the year ended June 30, 2011:


• Cash position at end of year $18.9M • Net cash burn for the year $3.9M • Cash outflows from operations $6.5M • Reported loss $8.9M


Commenting on the results, Starpharma CEO Dr. Jackie Fairley said: “We are pleased to report on the company’s activities in 2010/11, a year which has seen the achievement of important milestones for VivaGel®


and some exciting developments in


the strategic diversification of our platform techno- logy. Starpharma has ended the year with a strong cash position, an increasing number of partnered programs across several industry sectors, and strong support from our investor base, both local and inter- national.” Moreover, Starpharma and GlaxoSmithKline (GSK) announced that GSK was awarded a grant to advan-


11-08 :: August 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103